---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030817"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:40:40.538460+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q3 2022 net loss improves to $2.3M; cash $57.8M, pipeline on track

## Summary
- Net loss of $2.3M ($0.21/shr) vs $4.1M ($0.36/shr) in Q3 2021; R&D expenses fell to $0.7M.
- Cash, equivalents and marketable securities $57.8M as of Sep 30, 2022; cash runway into 2025.
- Harmonic Phase 2 trial (LP-300) activated first two US sites; new U.S. patent issued for LP-300 through 2032.
- IND-enabling studies for LP-184 and LP-284 expected complete Q1 2023; Phase 1 launches targeted H1 2023.

## SEC filing metadata
- accession: 0001493152-22-030817
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/0001493152-22-030817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030817
- JSON: https://secwatch.observer/filing/0001493152-22-030817.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030817.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30 , 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/0001493152-22-030817-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.